A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M et al. Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.94. [Epub ahead of print].
Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection.
Lisenko K et al. J Clin Apher. 2016 Apr 20. doi: 10.1002/jca.21463. [Epub ahead of print].
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Valtola J et al. Transfusion. 2016 Apr 4. doi: 10.1111/trf.13574. [Epub ahead of print].
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA et al. BMC Cancer. 2016 Apr 25;16(1):290. doi: 10.1186/s12885-016-2321-2.
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
Lee HS et al. Ann Hematol. 2016 Apr 6. [Epub ahead of print].
Analysis of renal impairment in MM-003, a phase 3 study of pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC et al. Haematologica. 2016 Apr 14. pii: haematol.2015.137083. [Epub ahead of print].
Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y et al. Br J Haematol. 2016 Apr 8. doi: 10.1111/bjh.14086. [Epub ahead of print].
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C et al. Ann Hematol. 2016 Apr 11. [Epub ahead of print].
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S et al. Ann Hematol. 2016 Apr 5. [Epub ahead of print].
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE et al. Eur J Haematol. 2016 Mar 29. doi: 10.1111/ejh.12758. [Epub ahead of print].